Taiho Pharmaceutical

Taiho Pharmaceutical (大鵬薬品工業, Taihō Yakuhin Kōgyō) is a Japanese pharmaceutical company, subsidiary of Otsuka Holdings. The company focuses on developing cancer treatments.

Taiho Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. Taiho is an R&D-driven specialty pharma focusing on the three fields of oncology, allergies and immunology, and urology. Taiho is the Japanese second-largest by prescription oral oncology sales. The company mainly covers oncology related therapeutic area: stomach cancer, colorectal cancer, pancreatic cancer, breast cancer and more. Taiho engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Taiho is a full member of the Japan Pharmaceutical Manufacturers Association (JPMA).

In March 2013, Taiho has over 2,500 employees worldwide and achieved $1.3 billion USD in revenue during the 2012 fiscal year. http://www.taiho.co.jp/english/corporation/highlights.html

1963 Taiho Pharmaceutical Co., Ltd. established; Yukio Kobayashi appointed as president and representative director Capital increased to ¥100 million A representative from each of the 49 distributors nationwide assumes the position of Board Member

1964 In-house production plant established in Naruto, Tokushima Prefecture Nine new offices established throughout Japan, centered around the head office in Tokyo, as sales bases

1965 Capital increased from ¥100 to ¥200 million

1969 License with the Soviet Union to introduce Futraful in Japan

1971 Lyophilized formulation plant (seventh plant) completed in the Imagire Industrial Park in Tokushima

1974 Proprietary Medicine Division established

1975 Advertising strategy (TV ads) started for Tiovita Drink

1976 Business alliance formed with Nichiban Co., Ltd., with equity participation by Taiho Pharmaceutical

1977 Employee welfare facility Otsuka Amagi Mountain Villa completed

1978 Business alliance formed with Kotai Kasei Co., Ltd., with equity participation by Taiho Pharmaceutical GMP-compliant injection drug plant completed within the Tokushima Plant; full plant integration also completed

1979 Advertising strategy (TV ads) started for Solmack

1980 GLP-compliant Tokushima Research and Development Laboratory and Safety Laboratory completed in Tokushima

...
Wikipedia